The Genomics & Microarray Core provides scientific services and computational support for SPORE projects using DNA microarrays. The facility is contained within the UNC Genomics Core & Microarray Facility housed in the Lineberger Comprehensive Cancer Center. It maintains centralized equipment for microarray production, utilization, and analysis, including an Affymetrix system for oligonucleotide arrays on chips. The Core produces affordable, customized high-density cDNA microarrays on glass slides. To maximize efficiency and generate consistent quality results, the Genomics & Microarray Core will provide complete research services to SPORE projects. Investigators will isolate RNA and submit samples. The facility will prepare fluorescent probes and hybridize them to either homemade or commercially available arrays. In conjunction with the UNC Center for Bioinformatics, the Genomics & Microarray Core will provide the required computer hardware and analysis programs to collect, store, and characterize the large data sets generated by microarray research. UNC has implemented the GenoMax database and software package (Informax) to serve these computational needs. SPORE investigators will utilize this resource as well as database tools available through our collaborators at Stanford University. The Genomics & Microarray Core will support four of the SPORE projects. Its use will most likely expand to other projects and development studies as investigators recognize the advantages of this cutting edge technology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA058223-09A1
Application #
6547707
Study Section
Special Emphasis Panel (ZCA1)
Project Start
1992-09-30
Project End
2006-07-31
Budget Start
Budget End
Support Year
9
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Matsunuma, Ryoichi; Chan, Doug W; Kim, Beom-Jun et al. (2018) DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proc Natl Acad Sci U S A 115:E11978-E11987
Panda, Anshuman; de Cubas, Aguirre A; Stein, Mark et al. (2018) Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight 3:
Sharma, Priyanka; López-Tarruella, Sara; García-Saenz, José Angel et al. (2018) Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clin Cancer Res 24:5820-5829
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
Kumar, Sunil; Lindsay, Daniel; Chen, Q Brent et al. (2018) Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ. NPJ Breast Cancer 4:39
Smith, Christof C; Beckermann, Kathryn E; Bortone, Dante S et al. (2018) Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J Clin Invest 128:4804-4820
Wheeler, Stephanie B; Spencer, Jennifer C; Pinheiro, Laura C et al. (2018) Financial Impact of Breast Cancer in Black Versus White Women. J Clin Oncol 36:1695-1701
Hong, Chi-Chen; Sucheston-Campbell, Lara E; Liu, Song et al. (2018) Genetic Variants in Immune-Related Pathways and Breast Cancer Risk in African American Women in the AMBER Consortium. Cancer Epidemiol Biomarkers Prev 27:321-330
Tanioka, Maki; Mott, Kevin R; Hollern, Daniel P et al. (2018) Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer. Genome Med 10:86
Tanioka, Maki; Fan, Cheng; Parker, Joel S et al. (2018) Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clin Cancer Res 24:5292-5304

Showing the most recent 10 out of 598 publications